drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00342 | DB12035 | 1,181 | 943 | [
"DDInter1770",
"DDInter1641"
] | Terfenadine | Sarecycline | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
1181,
24,
943
]
],
[
[
1181,
24,
1456
],
[
1456,
24,
943
]
],
[
[
1181,
24,
1619
],
[
1619,
63,
943
]
],
[
[
1181,
25,
868
],
[
868,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ruca... |
DB01181 | DB01589 | 1,532 | 481 | [
"DDInter906",
"DDInter1552"
] | Ifosfamide | Quazepam | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
1532,
24,
481
]
],
[
[
1532,
63,
1216
],
[
1216,
1,
481
]
],
[
[
1532,
24,
1418
],
[
1418,
1,
481
]
],
[
[
1532,
63,
905
],
[
905,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Quazepam (Compound)
Ifosfa... |
DB01058 | DB06636 | 978 | 1,623 | [
"DDInter1510",
"DDInter980"
] | Praziquantel | Isavuconazonium | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
978,
24,
1623
]
],
[
[
978,
24,
1487
],
[
1487,
24,
1623
]
],
[
[
978,
24,
214
],
[
214,
63,
1623
]
],
[
[
978,
62,
510
],
[
510,
... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00220 | DB00938 | 798 | 455 | [
"DDInter1276",
"DDInter1635"
] | Nelfinavir | Salmeterol | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Major | 2 | [
[
[
798,
25,
455
]
],
[
[
798,
6,
6799
],
[
6799,
45,
455
]
],
[
[
798,
7,
9187
],
[
9187,
46,
455
]
],
[
[
798,
18,
5833
],
[
5833,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
"Salmete... | Nelfinavir (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Salmeterol (Compound)
Nelfinavir (Compound) upregulates EDEM1 (Gene) and EDEM1 (Gene) is upregulated by Salmeterol (Compound)
Nelfinavir (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Salmeterol (Compound)
Nelfinavir (Comp... |
DB00494 | DB01041 | 1,533 | 770 | [
"DDInter646",
"DDInter1789"
] | Entacapone | Thalidomide | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa conce... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1533,
24,
770
]
],
[
[
1533,
21,
29425
],
[
29425,
60,
770
]
],
[
[
1533,
24,
849
],
[
849,
63,
770
]
],
[
[
1533,
63,
1614
],
[
1614,... | [
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Entacapone",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial ischaemia"
],
[
"Myocardial ischaemia",
"{u... | Entacapone (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Thalidomide (Compound)
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases ... |
DB00486 | DB01021 | 1,614 | 674 | [
"DDInter1253",
"DDInter1861"
] | Nabilone | Trichlormethiazide | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
1614,
24,
674
]
],
[
[
1614,
24,
1014
],
[
1014,
40,
674
]
],
[
[
1614,
24,
178
],
[
178,
1,
674
]
],
[
[
1614,
63,
323
],
[
323,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Trichlorme... |
DB00005 | DB12332 | 1,057 | 1,619 | [
"DDInter687",
"DDInter1626"
] | Etanercept | Rucaparib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
1057,
25,
1619
]
],
[
[
1057,
24,
112
],
[
112,
23,
1619
]
],
[
[
1057,
25,
259
],
[
259,
24,
1619
]
],
[
[
1057,
24,
151
],
[
151,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Etanercept may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cau... |
DB00313 | DB11130 | 556 | 407 | [
"DDInter1913",
"DDInter1344"
] | Valproic acid | Opium | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
556,
24,
407
]
],
[
[
556,
24,
662
],
[
662,
24,
407
]
],
[
[
556,
63,
475
],
[
475,
24,
407
]
],
[
[
556,
23,
752
],
[
752,
24,... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Morphine and M... |
DB01365 | DB13928 | 280 | 1,385 | [
"DDInter1151",
"DDInter1660"
] | Mephentermine | Semaglutide | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
280,
24,
1385
]
],
[
[
280,
40,
1445
],
[
1445,
24,
1385
]
],
[
[
280,
74,
73
],
[
73,
24,
1385
]
],
[
[
280,
63,
1144
],
[
1144,
... | [
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} ma... | Mephentermine (Compound) resembles Pseudoephedrine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Mephentermine (Compound) resembles Phentermine (Compound) and Mephentermine may cause a moderate interaction that could exacerbate diseases when t... |
DB00295 | DB11978 | 475 | 124 | [
"DDInter1244",
"DDInter822"
] | Morphine | Glasdegib | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
475,
24,
124
]
],
[
[
475,
25,
180
],
[
180,
63,
124
]
],
[
[
475,
24,
9
],
[
9,
24,
124
]
],
[
[
475,
24,
730
],
[
730,
63,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
... | Morphine may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine... |
DB00899 | DB01191 | 411 | 1,039 | [
"DDInter1579",
"DDInter518"
] | Remifentanil | Dexfenfluramine | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
411,
25,
1039
]
],
[
[
411,
24,
578
],
[
578,
63,
1039
]
],
[
[
411,
63,
1503
],
[
1503,
24,
1039
]
],
[
[
411,
25,
222
],
[
222,
... | [
[
[
"Remifentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"T... | Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Lindane and ... |
DB08918 | DB09075 | 41 | 498 | [
"DDInter1059",
"DDInter621"
] | Levomilnacipran | Edoxaban | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
41,
24,
498
]
],
[
[
41,
64,
222
],
[
222,
24,
498
]
],
[
[
41,
1,
901
],
[
901,
24,
498
]
],
[
[
41,
63,
582
],
[
582,
25,
... | [
[
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Levomilnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"S... | Levomilnacipran may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Levomilnacipran (Compound) resembles Milnacipran (Compound) and Milnacipran may cause a moderate interaction that could ex... |
DB01045 | DB09079 | 463 | 1,496 | [
"DDInter1590",
"DDInter1296"
] | Rifampicin | Nintedanib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Major | 2 | [
[
[
463,
25,
1496
]
],
[
[
463,
25,
741
],
[
741,
63,
1496
]
],
[
[
463,
24,
609
],
[
609,
24,
1496
]
],
[
[
463,
25,
840
],
[
840,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} m... | Rifampicin may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin ma... |
DB00860 | DB09037 | 891 | 920 | [
"DDInter1513",
"DDInter1413"
] | Prednisolone | Pembrolizumab | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and ... | Moderate | 1 | [
[
[
891,
24,
920
]
],
[
[
891,
1,
175
],
[
175,
24,
920
]
],
[
[
891,
40,
1573
],
[
1573,
24,
920
]
],
[
[
891,
25,
770
],
[
770,
25... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may ca... | Prednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Pembrolizumab
Prednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB05812 | DB08875 | 1,374 | 1,618 | [
"DDInter8",
"DDInter262"
] | Abiraterone | Cabozantinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1374,
25,
1618
]
],
[
[
1374,
23,
1135
],
[
1135,
62,
1618
]
],
[
[
1374,
62,
112
],
[
112,
23,
1618
]
],
[
[
1374,
24,
384
],
[
384,
... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metroni... |
DB00679 | DB00855 | 684 | 213 | [
"DDInter1796",
"DDInter72"
] | Thioridazine | Aminolevulinic acid | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
684,
25,
213
]
],
[
[
684,
7,
18134
],
[
18134,
46,
213
]
],
[
[
684,
18,
10547
],
[
10547,
46,
213
]
],
[
[
684,
18,
17504
],
[
17504... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Thioridazine",
"{u} (Compound) upregulates {v} (Gene)",
"POLD4"
],
[
"POLD4",
"{u} (Gene) is upregulated by {v} (Com... | Thioridazine (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Aminolevulinic acid (Compound)
Thioridazine (Compound) downregulates YTHDF1 (Gene) and YTHDF1 (Gene) is upregulated by Aminolevulinic acid (Compound)
Thioridazine (Compound) downregulates TMEM109 (Gene) and TMEM109 (Gene) is downregulat... |
DB00250 | DB04865 | 10 | 4 | [
"DDInter475",
"DDInter1335"
] | Dapsone | Omacetaxine mepesuccinate | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
10,
24,
4
]
],
[
[
10,
6,
7720
],
[
7720,
46,
4
]
],
[
[
10,
24,
770
],
[
770,
24,
4
]
],
[
[
10,
24,
381
],
[
381,
63,
4
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v}... | Dapsone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine me... |
DB00344 | DB05812 | 1,302 | 1,374 | [
"DDInter1543",
"DDInter8"
] | Protriptyline | Abiraterone | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1302,
24,
1374
]
],
[
[
1302,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
1302,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
1302,
23,
112
],
[
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Comp... | Protriptyline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Protriptyline (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Protriptyline may cause a minor interaction that can limit clinical effect... |
DB09312 | DB05679 | 967 | 1,683 | [
"DDInter106",
"DDInter1907"
] | Antithymocyte immunoglobulin (rabbit) | Ustekinumab | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
967,
63,
1683
]
],
[
[
967,
23,
1461
],
[
1461,
23,
1683
]
],
[
[
967,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
967,
24,
1129
],
[
1129,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects whe... | Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clini... |
DB01087 | DB08881 | 1,520 | 868 | [
"DDInter1520",
"DDInter1925"
] | Primaquine | Vemurafenib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1520,
25,
868
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1520,
21,
28658
],
[
28658,
60,
868
]
],
[
[
1520,
62,
211
],
[
211,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemura... | Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Primaquine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Vemurafenib (Compound)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolte... |
DB00357 | DB04835 | 1,051 | 1,655 | [
"DDInter71",
"DDInter1125"
] | Aminoglutethimide | Maraviroc | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
1051,
24,
1655
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
1655
]
],
[
[
1051,
21,
28921
],
[
28921,
60,
1655
]
],
[
[
1051,
24,
1419
],
[
1... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v}... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Maraviroc (Compound)
Aminoglutethimide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Maraviroc (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00414 | DB00615 | 590 | 690 | [
"DDInter16",
"DDInter1589"
] | Acetohexamide | Rifabutin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Moderate | 1 | [
[
[
590,
24,
690
]
],
[
[
590,
24,
463
],
[
463,
1,
690
]
],
[
[
590,
63,
1101
],
[
1101,
23,
690
]
],
[
[
590,
25,
86
],
[
86,
62,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can... |
DB00939 | DB08870 | 1,338 | 850 | [
"DDInter1135",
"DDInter228"
] | Meclofenamic acid | Brentuximab vedotin | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1338,
24,
850
]
],
[
[
1338,
63,
267
],
[
267,
24,
850
]
],
[
[
1338,
74,
1512
],
[
1512,
24,
850
]
],
[
[
1338,
25,
1468
],
[
1468,
... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalt... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Meclofenamic acid (Compound) resembles Diclofenac (Compound) and Meclofenamic acid may cause a m... |
DB00771 | DB04946 | 262 | 924 | [
"DDInter397",
"DDInter907"
] | Clidinium | Iloperidone | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
262,
24,
924
]
],
[
[
262,
63,
1664
],
[
1664,
1,
924
]
],
[
[
262,
63,
1425
],
[
1425,
25,
924
]
],
[
[
262,
24,
519
],
[
519,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interac... |
DB00607 | DB04845 | 1,249 | 309 | [
"DDInter1256",
"DDInter1001"
] | Nafcillin | Ixabepilone | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
1249,
24,
309
]
],
[
[
1249,
6,
8374
],
[
8374,
45,
309
]
],
[
[
1249,
21,
28725
],
[
28725,
60,
309
]
],
[
[
1249,
24,
1419
],
[
1419... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Nafcillin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nafcillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Nafcillin (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Ixabepilone (Compound)
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and I... |
DB01095 | DB08870 | 671 | 850 | [
"DDInter769",
"DDInter228"
] | Fluvastatin | Brentuximab vedotin | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
671,
24,
850
]
],
[
[
671,
1,
788
],
[
788,
24,
850
]
],
[
[
671,
63,
896
],
[
896,
24,
850
]
],
[
[
671,
24,
1033
],
[
1033,
63... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fluvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may ... | Fluvastatin (Compound) resembles Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interacti... |
DB00188 | DB00549 | 168 | 522 | [
"DDInter222",
"DDInter1955"
] | Bortezomib | Zafirlukast | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Moderate | 1 | [
[
[
168,
24,
522
]
],
[
[
168,
6,
7950
],
[
7950,
45,
522
]
],
[
[
168,
21,
28935
],
[
28935,
60,
522
]
],
[
[
168,
24,
1091
],
[
1091,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)"... | Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Zafirlukast (Compound)
Bortezomib (Compound) causes Hyperbilirubinaemia (Side Effect) and Hyperbilirubinaemia (Side Effect) is caused by Zafirlukast (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00092 | DB01157 | 58 | 304 | [
"DDInter40",
"DDInter1875"
] | Alefacept | Trimetrexate | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Moderate | 1 | [
[
[
58,
24,
304
]
],
[
[
58,
63,
599
],
[
599,
24,
304
]
],
[
[
58,
24,
1270
],
[
1270,
63,
304
]
],
[
[
58,
24,
139
],
[
139,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified... |
DB00647 | DB00704 | 675 | 267 | [
"DDInter528",
"DDInter1263"
] | Dextropropoxyphene | Naltrexone | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Major | 2 | [
[
[
675,
25,
267
]
],
[
[
675,
64,
475
],
[
475,
25,
267
]
],
[
[
675,
6,
6291
],
[
6291,
45,
267
]
],
[
[
675,
18,
2183
],
[
2183,
... | [
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
... | Dextropropoxyphene may lead to a major life threatening interaction when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Naltrexone
Dextropropoxyphene (Compound) binds OPRD1 (Gene) and OPRD1 (Gene) is bound by Naltrexone (Compound)
Dextropropoxyphene (Compound) downregu... |
DB00748 | DB08897 | 662 | 1,429 | [
"DDInter297",
"DDInter22"
] | Carbinoxamine | Aclidinium | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
662,
24,
1429
]
],
[
[
662,
63,
352
],
[
352,
24,
1429
]
],
[
[
662,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
662,
21,
28817
],
[
28817,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mep... |
DB00277 | DB00401 | 1,031 | 84 | [
"DDInter1791",
"DDInter1298"
] | Theophylline | Nisoldipine | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Minor | 0 | [
[
[
1031,
23,
84
]
],
[
[
1031,
23,
336
],
[
336,
40,
84
]
],
[
[
1031,
6,
7950
],
[
7950,
45,
84
]
],
[
[
1031,
21,
29789
],
[
29789,
... | [
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nisoldipine"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nifedipine"
],
[
... | Theophylline may cause a minor interaction that can limit clinical effects when taken with Nifedipine and Nifedipine (Compound) resembles Nisoldipine (Compound)
Theophylline (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nisoldipine (Compound)
Theophylline (Compound) causes Supraventricular tachycardia (S... |
DB14711 | DB14724 | 779 | 48 | [
"DDInter1680",
"DDInter634"
] | Smallpox (Vaccinia) Vaccine, Live | Emapalumab | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Major | 2 | [
[
[
779,
25,
48
]
],
[
[
779,
64,
713
],
[
713,
24,
48
]
],
[
[
779,
64,
713
],
[
713,
24,
1456
],
[
1456,
24,
48
]
],
[
[
779,
64,
... | [
[
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Emapalumab"
]
],
[
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fu... | Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when ta... |
DB00047 | DB00197 | 176 | 1,324 | [
"DDInter932",
"DDInter1881"
] | Insulin glargine | Troglitazone | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Moderate | 1 | [
[
[
176,
24,
1324
]
],
[
[
176,
23,
333
],
[
333,
23,
1324
]
],
[
[
176,
24,
1101
],
[
1101,
62,
1324
]
],
[
[
176,
23,
1103
],
[
1103,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
]
],
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
... | Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Troglitazone
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Bexaroten... |
DB00277 | DB01336 | 1,031 | 545 | [
"DDInter1791",
"DDInter1198"
] | Theophylline | Metocurine | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine. | Moderate | 1 | [
[
[
1031,
24,
545
]
],
[
[
1031,
24,
1217
],
[
1217,
40,
545
]
],
[
[
1031,
24,
1194
],
[
1194,
23,
545
]
],
[
[
1031,
1,
746
],
[
746,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metocurine"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tubocurarine"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Tubocurarine and Tubocurarine (Compound) resembles Metocurine (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that ... |
DB00877 | DB01159 | 629 | 419 | [
"DDInter1678",
"DDInter854"
] | Sirolimus | Halothane | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Moderate | 1 | [
[
[
629,
24,
419
]
],
[
[
629,
6,
8374
],
[
8374,
45,
419
]
],
[
[
629,
24,
477
],
[
477,
63,
419
]
],
[
[
629,
25,
609
],
[
609,
63... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halothane (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Halothane
Sirolimus may lead to ... |
DB06663 | DB11837 | 1,154 | 1,297 | [
"DDInter1398",
"DDInter1351"
] | Pasireotide | Osilodrostat | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
1154,
25,
1297
]
],
[
[
1154,
62,
112
],
[
112,
23,
1297
]
],
[
[
1154,
23,
466
],
[
466,
62,
1297
]
],
[
[
1154,
64,
623
],
[
623,
... | [
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Pasireotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide and ... |
DB09312 | DB11003 | 967 | 748 | [
"DDInter103",
"DDInter100"
] | Antilymphocyte immunoglobulin (horse) | Anthrax vaccine | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
967,
24,
748
]
],
[
[
967,
25,
676
],
[
676,
63,
748
]
],
[
[
967,
63,
1683
],
[
1683,
24,
748
]
],
[
[
967,
64,
1057
],
[
1057,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken w... | Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbat... |
DB00604 | DB00863 | 1,425 | 1,194 | [
"DDInter385",
"DDInter1568"
] | Cisapride | Ranitidine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Minor | 0 | [
[
[
1425,
23,
1194
]
],
[
[
1425,
6,
8374
],
[
8374,
45,
1194
]
],
[
[
1425,
64,
798
],
[
798,
23,
1194
]
],
[
[
1425,
25,
1664
],
[
1664,... | [
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Cisapride (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ranitidine (Compound)
Cisapride may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Cisapride may lead to a major life th... |
DB09312 | DB09322 | 967 | 1,114 | [
"DDInter103",
"DDInter1966"
] | Antilymphocyte immunoglobulin (horse) | Zinc sulfate | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
967,
23,
1114
]
],
[
[
967,
63,
66
],
[
66,
23,
1114
]
],
[
[
967,
64,
1057
],
[
1057,
23,
1114
]
],
[
[
967,
24,
270
],
[
270,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases wh... | Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interactio... |
DB00015 | DB01138 | 582 | 804 | [
"DDInter1585",
"DDInter1726"
] | Reteplase | Sulfinpyrazone | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
582,
24,
804
]
],
[
[
582,
24,
998
],
[
998,
1,
804
]
],
[
[
582,
24,
1274
],
[
1274,
24,
804
]
],
[
[
582,
24,
1496
],
[
1496,
... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interact... |
DB00014 | DB04946 | 521 | 924 | [
"DDInter839",
"DDInter907"
] | Goserelin | Iloperidone | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
521,
25,
924
]
],
[
[
521,
24,
1664
],
[
1664,
1,
924
]
],
[
[
521,
25,
1425
],
[
1425,
25,
924
]
],
[
[
521,
24,
519
],
[
519,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidon... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Goserelin may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken... |
DB00446 | DB12941 | 597 | 466 | [
"DDInter351",
"DDInter481"
] | Chloramphenicol | Darolutamide | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
597,
23,
466
]
],
[
[
597,
24,
1623
],
[
1623,
23,
466
]
],
[
[
597,
25,
484
],
[
484,
23,
466
]
],
[
[
597,
63,
376
],
[
376,
2... | [
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Chloramphenicol may lead to a major life threatening interaction when taken with Entrectinib and ... |
DB01105 | DB11837 | 222 | 1,297 | [
"DDInter1665",
"DDInter1351"
] | Sibutramine | Osilodrostat | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Minor | 0 | [
[
[
222,
23,
1297
]
],
[
[
222,
24,
578
],
[
578,
24,
1297
]
],
[
[
222,
63,
401
],
[
401,
24,
1297
]
],
[
[
222,
62,
752
],
[
752,
... | [
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and ... |
DB00065 | DB08895 | 581 | 976 | [
"DDInter923",
"DDInter1825"
] | Infliximab | Tofacitinib | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
581,
25,
976
]
],
[
[
581,
23,
1193
],
[
1193,
62,
976
]
],
[
[
581,
23,
1461
],
[
1461,
23,
976
]
],
[
[
581,
24,
200
],
[
200,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vita... |
DB00313 | DB00405 | 556 | 128 | [
"DDInter1913",
"DDInter517"
] | Valproic acid | Dexbrompheniramine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
556,
24,
128
]
],
[
[
556,
24,
662
],
[
662,
63,
128
]
],
[
[
556,
63,
475
],
[
475,
24,
128
]
],
[
[
556,
24,
1242
],
[
1242,
2... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with M... |
DB09054 | DB11581 | 384 | 1,456 | [
"DDInter905",
"DDInter1926"
] | Idelalisib | Venetoclax | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
384,
25,
1456
]
],
[
[
384,
64,
1135
],
[
1135,
23,
1456
]
],
[
[
384,
63,
536
],
[
536,
24,
1456
]
],
[
[
384,
24,
241
],
[
241,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause ... |
DB00629 | DB01234 | 390 | 1,220 | [
"DDInter844",
"DDInter513"
] | Guanabenz | Dexamethasone | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
390,
24,
1220
]
],
[
[
390,
24,
870
],
[
870,
1,
1220
]
],
[
[
390,
63,
175
],
[
175,
40,
1220
]
],
[
[
390,
24,
617
],
[
617,
4... | [
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexam... |
DB00801 | DB01105 | 1,563 | 222 | [
"DDInter850",
"DDInter1665"
] | Halazepam | Sibutramine | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1563,
24,
222
]
],
[
[
1563,
24,
609
],
[
609,
62,
222
]
],
[
[
1563,
63,
752
],
[
752,
23,
222
]
],
[
[
1563,
24,
629
],
[
629,
... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[... | Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and C... |
DB00108 | DB09312 | 1,066 | 967 | [
"DDInter1268",
"DDInter103"
] | Natalizumab | Antilymphocyte immunoglobulin (horse) | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Major | 2 | [
[
[
1066,
25,
967
]
],
[
[
1066,
23,
1193
],
[
1193,
62,
967
]
],
[
[
1066,
25,
1683
],
[
1683,
24,
967
]
],
[
[
1066,
25,
1531
],
[
1531,... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"... | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Antilymphocyte immunoglobulin (horse)
Natalizumab may lead to a major life threatening interaction when taken with Ust... |
DB00039 | DB00307 | 1,253 | 1,101 | [
"DDInter1380",
"DDInter202"
] | Palifermin | Bexarotene | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Moderate | 1 | [
[
[
1253,
24,
1101
]
],
[
[
1253,
24,
1419
],
[
1419,
62,
1101
]
],
[
[
1253,
24,
168
],
[
168,
23,
1101
]
],
[
[
1253,
24,
134
],
[
134,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib m... |
DB00816 | DB01193 | 1,674 | 819 | [
"DDInter1346",
"DDInter12"
] | Orciprenaline | Acebutolol | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
1674,
24,
819
]
],
[
[
1674,
25,
887
],
[
887,
1,
819
]
],
[
[
1674,
63,
1121
],
[
1121,
1,
819
]
],
[
[
1674,
6,
3576
],
[
3576,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
],
[
"Pindol... | Orciprenaline may lead to a major life threatening interaction when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol (Compound) resembles Acebutolol (Compound)
Orciprenaline... |
DB05679 | DB09322 | 1,683 | 1,114 | [
"DDInter1907",
"DDInter1966"
] | Ustekinumab | Zinc sulfate | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
1683,
23,
1114
]
],
[
[
1683,
63,
66
],
[
66,
23,
1114
]
],
[
[
1683,
24,
1093
],
[
1093,
62,
1114
]
],
[
[
1683,
64,
1057
],
[
1057,
... | [
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixek... |
DB00450 | DB08881 | 78 | 868 | [
"DDInter603",
"DDInter1925"
] | Droperidol | Vemurafenib | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
78,
25,
868
]
],
[
[
78,
21,
28681
],
[
28681,
60,
868
]
],
[
[
78,
23,
112
],
[
112,
23,
868
]
],
[
[
78,
24,
480
],
[
480,
24,... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Droperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caus... | Droperidol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Vemurafenib (Compound)
Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when t... |
DB00529 | DB00757 | 789 | 1,166 | [
"DDInter779",
"DDInter581"
] | Foscarnet | Dolasetron | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
789,
25,
1166
]
],
[
[
789,
21,
28803
],
[
28803,
60,
1166
]
],
[
[
789,
23,
112
],
[
112,
62,
1166
]
],
[
[
789,
24,
688
],
[
688,
... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Anaemia"
],
[
"Anaemia",
"{u} (Side Effect) is caused by {v} (Compound)"... | Foscarnet (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Dolasetron (Compound)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dolasetron
... |
DB00197 | DB00980 | 1,324 | 969 | [
"DDInter1881",
"DDInter1564"
] | Troglitazone | Ramelteon | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
1324,
24,
969
]
],
[
[
1324,
24,
1619
],
[
1619,
63,
969
]
],
[
[
1324,
24,
1419
],
[
1419,
24,
969
]
],
[
[
1324,
23,
1101
],
[
1101,... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatini... |
DB00317 | DB09061 | 883 | 1,627 | [
"DDInter810",
"DDInter284"
] | Gefitinib | Cannabidiol | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
883,
24,
1627
]
],
[
[
883,
24,
723
],
[
723,
23,
1627
]
],
[
[
883,
24,
760
],
[
760,
62,
1627
]
],
[
[
883,
63,
600
],
[
600,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicista... |
DB00569 | DB06209 | 553 | 256 | [
"DDInter775",
"DDInter1508"
] | Fondaparinux | Prasugrel | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
553,
25,
256
]
],
[
[
553,
21,
28681
],
[
28681,
60,
256
]
],
[
[
553,
23,
944
],
[
944,
62,
256
]
],
[
[
553,
24,
901
],
[
901,
... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Fondaparinux",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is ca... | Fondaparinux (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Fondaparinux may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken w... |
DB00620 | DB12130 | 175 | 1,017 | [
"DDInter1855",
"DDInter1094"
] | Triamcinolone | Lorlatinib | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
175,
24,
1017
]
],
[
[
175,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
175,
63,
590
],
[
590,
24,
1017
]
],
[
[
175,
25,
976
],
[
976,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and... |
DB00242 | DB08880 | 1,064 | 1,510 | [
"DDInter392",
"DDInter1771"
] | Cladribine | Teriflunomide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1064,
25,
1510
]
],
[
[
1064,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
1064,
24,
129
],
[
129,
63,
1510
]
],
[
[
1064,
25,
1136
],
[
1136... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzal... |
DB00515 | DB05351 | 589 | 101 | [
"DDInter387",
"DDInter519"
] | Cisplatin | Dexlansoprazole | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generatio... | Moderate | 1 | [
[
[
589,
24,
101
]
],
[
[
589,
24,
1468
],
[
1468,
62,
101
]
],
[
[
589,
24,
361
],
[
361,
24,
101
]
],
[
[
589,
24,
1381
],
[
1381,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin ... |
DB00455 | DB00857 | 1,601 | 1,387 | [
"DDInter1091",
"DDInter1768"
] | Loratadine | Terbinafine | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
1601,
24,
1387
]
],
[
[
1601,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
1601,
18,
16974
],
[
16974,
57,
1387
]
],
[
[
1601,
21,
28822
],
[
... | [
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Loratadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Loratadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Loratadine (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Terbinafine (Compound)
Loratadine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Terbinafine (Compound)
L... |
DB01142 | DB14575 | 1,264 | 733 | [
"DDInter593",
"DDInter674"
] | Doxepin | Eslicarbazepine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1264,
24,
733
]
],
[
[
1264,
63,
272
],
[
272,
24,
733
]
],
[
[
1264,
64,
222
],
[
222,
24,
733
]
],
[
[
1264,
24,
1491
],
[
1491,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Doxepin may lead to a major life threatening interaction when taken with Sibutramine and Sibutrami... |
DB00924 | DB09488 | 1,405 | 103 | [
"DDInter454",
"DDInter23"
] | Cyclobenzaprine | Acrivastine | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1405,
24,
103
]
],
[
[
1405,
63,
85
],
[
85,
24,
103
]
],
[
[
1405,
25,
1264
],
[
1264,
24,
103
]
],
[
[
1405,
24,
537
],
[
537,
... | [
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],... | Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Cyclobenzaprine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause... |
DB00552 | DB01005 | 1,238 | 995 | [
"DDInter1425",
"DDInter894"
] | Pentostatin | Hydroxyurea | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
1238,
24,
995
]
],
[
[
1238,
5,
11555
],
[
11555,
44,
995
]
],
[
[
1238,
21,
29276
],
[
29276,
60,
995
]
],
[
[
1238,
23,
1299
],
[
12... | [
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Pentostatin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dis... | Pentostatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Hydroxyurea (Compound)
Pentostatin (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Hydroxyurea (Compound)
Pentostatin may cause a minor interaction that can limit clinical eff... |
DB00334 | DB00434 | 867 | 13 | [
"DDInter1326",
"DDInter459"
] | Olanzapine | Cyproheptadine | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
867,
24,
13
]
],
[
[
867,
24,
104
],
[
104,
63,
13
]
],
[
[
867,
6,
10104
],
[
10104,
45,
13
]
],
[
[
867,
10,
11584
],
[
11584,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Olanzapine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Cyproheptadine (Compound)
Olanzapine... |
DB00201 | DB00640 | 1,684 | 1,585 | [
"DDInter263",
"DDInter31"
] | Caffeine | Adenosine | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but ... | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Moderate | 1 | [
[
[
1684,
24,
1585
]
],
[
[
1684,
6,
9232
],
[
9232,
45,
1585
]
],
[
[
1684,
21,
28676
],
[
28676,
60,
1585
]
],
[
[
1684,
24,
1619
],
[
1... | [
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"ADORA2B"
],
[
"ADORA2B",
"{u} (Gene) is bound by {v} (Compound)",
... | Caffeine (Compound) binds ADORA2B (Gene) and ADORA2B (Gene) is bound by Adenosine (Compound)
Caffeine (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Adenosine (Compound)
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapar... |
DB00398 | DB00526 | 79 | 1,555 | [
"DDInter1702",
"DDInter1355"
] | Sorafenib | Oxaliplatin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
79,
24,
1555
]
],
[
[
79,
6,
17404
],
[
17404,
45,
1555
]
],
[
[
79,
23,
1247
],
[
1247,
62,
1555
]
],
[
[
79,
24,
1232
],
[
1232,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Sorafenib (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Oxaliplatin (Compound)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Oxaliplatin
Sorafenib ma... |
DB00685 | DB01050 | 1,299 | 848 | [
"DDInter1887",
"DDInter900"
] | Trovafloxacin | Ibuprofen | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1299,
24,
848
]
],
[
[
1299,
23,
1053
],
[
1053,
1,
848
]
],
[
[
1299,
21,
28652
],
[
28652,
60,
848
]
],
[
[
1299,
24,
286
],
[
286,
... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
],
... | Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Trovafloxacin (Compound) causes Colitis (Side Effect) and Colitis (Side Effect) is caused by Ibuprofen (Compound)
Trovafloxacin may cause a moderate interac... |
DB00598 | DB00816 | 1,523 | 1,674 | [
"DDInter1013",
"DDInter1346"
] | Labetalol | Orciprenaline | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Major | 2 | [
[
[
1523,
25,
1674
]
],
[
[
1523,
25,
874
],
[
874,
24,
1674
]
],
[
[
1523,
63,
1636
],
[
1636,
24,
1674
]
],
[
[
1523,
40,
11540
],
[
115... | [
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
]
],
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u... | Labetalol may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine m... |
DB00214 | DB05812 | 1,028 | 1,374 | [
"DDInter1836",
"DDInter8"
] | Torasemide | Abiraterone | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1028,
24,
1374
]
],
[
[
1028,
6,
3486
],
[
3486,
45,
1374
]
],
[
[
1028,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1028,
24,
112
],
[
11... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Torasemide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)"... | Torasemide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Abiraterone (Compound)
Torasemide (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazo... |
DB00924 | DB08881 | 1,405 | 868 | [
"DDInter454",
"DDInter1925"
] | Cyclobenzaprine | Vemurafenib | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1405,
24,
868
]
],
[
[
1405,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1405,
21,
29015
],
[
29015,
60,
868
]
],
[
[
1405,
25,
1039
],
[
1039... | [
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Cyclobenzaprine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Cyclobenzaprine (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Cyclobenzaprine may lead to a major life threatening interaction when taken with Dexfenflura... |
DB00075 | DB11817 | 541 | 1,259 | [
"DDInter1250",
"DDInter165"
] | Muromonab | Baricitinib | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
541,
25,
1259
]
],
[
[
541,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
541,
24,
949
],
[
949,
24,
1259
]
],
[
[
541,
24,
1129
],
[
1129,
... | [
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Muromonab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Muromonab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani... |
DB00005 | DB01222 | 1,057 | 617 | [
"DDInter687",
"DDInter246"
] | Etanercept | Budesonide | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Major | 2 | [
[
[
1057,
25,
617
]
],
[
[
1057,
25,
251
],
[
251,
1,
617
]
],
[
[
1057,
23,
1461
],
[
1461,
23,
617
]
],
[
[
1057,
23,
1193
],
[
1193,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
... | Etanercept may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical ef... |
DB00758 | DB01294 | 1,347 | 266 | [
"DDInter413",
"DDInter215"
] | Clopidogrel | Bismuth subsalicylate | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
1347,
24,
266
]
],
[
[
1347,
21,
28643
],
[
28643,
60,
266
]
],
[
[
1347,
25,
235
],
[
235,
63,
266
]
],
[
[
1347,
63,
475
],
[
475,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Clopidogrel",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Ef... | Clopidogrel (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Bismuth subsalicylate (Compound)
Clopidogrel may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Bismuth sub... |
DB00745 | DB00758 | 307 | 1,347 | [
"DDInter1236",
"DDInter413"
] | Modafinil | Clopidogrel | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
307,
24,
1347
]
],
[
[
307,
6,
7603
],
[
7603,
45,
1347
]
],
[
[
307,
7,
7626
],
[
7626,
46,
1347
]
],
[
[
307,
18,
10375
],
[
10375,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP2B6"
],
[
"CYP2B6",
"{u} (Gene) is bound by {v} (Compound)",
... | Modafinil (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Clopidogrel (Compound)
Modafinil (Compound) upregulates IL13RA1 (Gene) and IL13RA1 (Gene) is upregulated by Clopidogrel (Compound)
Modafinil (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Clopidogrel (Compound)
Modafini... |
DB00834 | DB00983 | 932 | 480 | [
"DDInter1215",
"DDInter776"
] | Mifepristone | Formoterol | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
932,
24,
480
]
],
[
[
932,
25,
1148
],
[
1148,
63,
480
]
],
[
[
932,
6,
12523
],
[
12523,
45,
480
]
],
[
[
932,
21,
28963
],
[
28963,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isop... | Mifepristone may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Mifepristone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound)
Mifepristone (Compound) c... |
DB00835 | DB01036 | 100 | 211 | [
"DDInter245",
"DDInter1832"
] | Brompheniramine | Tolterodine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
100,
24,
211
]
],
[
[
100,
35,
358
],
[
358,
40,
211
]
],
[
[
100,
1,
11296
],
[
11296,
40,
211
]
],
[
[
100,
24,
573
],
[
573,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases w... | Brompheniramine (Compound) resembles Orphenadrine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Tolterodine (Compound)
Brompheniramine (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenh... |
DB00366 | DB09272 | 1,594 | 412 | [
"DDInter600",
"DDInter632"
] | Doxylamine | Eluxadoline | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1594,
24,
412
]
],
[
[
1594,
24,
1105
],
[
1105,
24,
412
]
],
[
[
1594,
63,
475
],
[
475,
24,
412
]
],
[
[
1594,
74,
21
],
[
21,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine a... |
DB00443 | DB14975 | 251 | 988 | [
"DDInter195",
"DDInter1949"
] | Betamethasone | Voxelotor | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
251,
24,
988
]
],
[
[
251,
24,
629
],
[
629,
24,
988
]
],
[
[
251,
1,
1486
],
[
1486,
24,
988
]
],
[
[
251,
40,
870
],
[
870,
24... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Betamethasone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate int... |
DB00757 | DB04861 | 1,166 | 1,592 | [
"DDInter581",
"DDInter1271"
] | Dolasetron | Nebivolol | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Major | 2 | [
[
[
1166,
25,
1592
]
],
[
[
1166,
6,
12523
],
[
12523,
45,
1592
]
],
[
[
1166,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
1166,
24,
286
],
[
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nebivolol"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Nebivolo... | Dolasetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nebivolol (Compound)
Dolasetron (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and... |
DB00880 | DB06410 | 359 | 1,196 | [
"DDInter360",
"DDInter595"
] | Chlorothiazide | Doxercalciferol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Moderate | 1 | [
[
[
359,
24,
1196
]
],
[
[
359,
40,
1014
],
[
1014,
24,
1196
]
],
[
[
359,
24,
286
],
[
286,
63,
1196
]
],
[
[
359,
63,
1331
],
[
1331,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} ma... | Chlorothiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may caus... |
DB00047 | DB14006 | 176 | 972 | [
"DDInter932",
"DDInter370"
] | Insulin glargine | Choline salicylate | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
176,
24,
972
]
],
[
[
176,
24,
1573
],
[
1573,
24,
972
]
],
[
[
176,
24,
1573
],
[
1573,
23,
771
],
[
771,
62,
972
]
],
[
[
176,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednis... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with P... |
DB00736 | DB11791 | 660 | 785 | [
"DDInter676",
"DDInter287"
] | Esomeprazole | Capmatinib | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Minor | 0 | [
[
[
660,
23,
785
]
],
[
[
660,
40,
837
],
[
837,
23,
785
]
],
[
[
660,
1,
1215
],
[
1215,
23,
785
]
],
[
[
660,
24,
98
],
[
98,
24,
... | [
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capmatinib"
]
],
[
[
"Esomeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a m... | Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Esomeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Cap... |
DB08895 | DB12130 | 976 | 1,017 | [
"DDInter1825",
"DDInter1094"
] | Tofacitinib | Lorlatinib | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
976,
24,
1017
]
],
[
[
976,
63,
608
],
[
608,
23,
1017
]
],
[
[
976,
64,
1101
],
[
1101,
23,
1017
]
],
[
[
976,
64,
175
],
[
175,
... | [
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Tofacitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a ... |
DB06691 | DB09076 | 849 | 1,116 | [
"DDInter1155",
"DDInter1899"
] | Mepyramine | Umeclidinium | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
849,
24,
1116
]
],
[
[
849,
63,
1300
],
[
1300,
24,
1116
]
],
[
[
849,
24,
1429
],
[
1429,
24,
1116
]
],
[
[
849,
74,
662
],
[
662,
... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
],
[... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Ac... |
DB00196 | DB14881 | 600 | 180 | [
"DDInter743",
"DDInter1329"
] | Fluconazole | Oliceridine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
600,
25,
180
]
],
[
[
600,
23,
112
],
[
112,
23,
180
]
],
[
[
600,
24,
401
],
[
401,
24,
180
]
],
[
[
600,
63,
618
],
[
618,
24,... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and... |
DB00653 | DB08826 | 544 | 1,292 | [
"DDInter1120",
"DDInter489"
] | Magnesium sulfate | Deferiprone | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Moderate | 1 | [
[
[
544,
24,
1292
]
],
[
[
544,
21,
28936
],
[
28936,
60,
1292
]
],
[
[
544,
24,
460
],
[
460,
63,
1292
]
],
[
[
544,
24,
72
],
[
72,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Magnesium sulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u... | Magnesium sulfate (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Deferiprone (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could ex... |
DB01377 | DB01416 | 1,283 | 1,024 | [
"DDInter1119",
"DDInter326"
] | Magnesium oxide | Cefpodoxime | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Moderate | 1 | [
[
[
1283,
24,
1024
]
],
[
[
1283,
63,
665
],
[
665,
40,
1024
]
],
[
[
1283,
63,
1462
],
[
1462,
1,
1024
]
],
[
[
1283,
24,
286
],
[
286,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
... | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefpodoxime (Compound)
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Cefpodoxime... |
DB00372 | DB00486 | 999 | 1,614 | [
"DDInter1793",
"DDInter1253"
] | Thiethylperazine | Nabilone | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
999,
24,
1614
]
],
[
[
999,
24,
530
],
[
530,
1,
1614
]
],
[
[
999,
24,
887
],
[
887,
63,
1614
]
],
[
[
999,
63,
472
],
[
472,
2... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol may cause a moderate interaction that... |
DB00350 | DB00633 | 1,214 | 614 | [
"DDInter1226",
"DDInter520"
] | Minoxidil | Dexmedetomidine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Moderate | 1 | [
[
[
1214,
24,
614
]
],
[
[
1214,
63,
1648
],
[
1648,
24,
614
]
],
[
[
1214,
24,
530
],
[
530,
24,
614
]
],
[
[
1214,
24,
1264
],
[
1264,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and D... |
DB01124 | DB08820 | 1,411 | 1,478 | [
"DDInter1828",
"DDInter997"
] | Tolbutamide | Ivacaftor | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1411,
24,
1478
]
],
[
[
1411,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
1411,
24,
318
],
[
318,
23,
1478
]
],
[
[
1411,
63,
1230
],
[
12... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Tolbutamide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cause... | Tolbutamide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaf... |
DB00604 | DB01254 | 1,425 | 1,213 | [
"DDInter385",
"DDInter484"
] | Cisapride | Dasatinib | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
1425,
25,
1213
]
],
[
[
1425,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
1425,
18,
2801
],
[
2801,
57,
1213
]
],
[
[
1425,
23,
1247
],
[
124... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"... | Cisapride (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Cisapride (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Dasatinib (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxaz... |
DB01229 | DB08875 | 973 | 1,618 | [
"DDInter1377",
"DDInter262"
] | Paclitaxel | Cabozantinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
973,
24,
1618
]
],
[
[
973,
63,
112
],
[
112,
23,
1618
]
],
[
[
973,
63,
723
],
[
723,
24,
1618
]
],
[
[
973,
24,
384
],
[
384,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and ... |
DB01059 | DB06176 | 956 | 1,342 | [
"DDInter1313",
"DDInter1616"
] | Norfloxacin | Romidepsin | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
956,
24,
1342
]
],
[
[
956,
62,
112
],
[
112,
23,
1342
]
],
[
[
956,
63,
485
],
[
485,
24,
1342
]
],
[
[
956,
24,
1520
],
[
1520,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and P... |
DB00073 | DB00163 | 1,394 | 1,461 | [
"DDInter1608",
"DDInter1943"
] | Rituximab | Vitamin E | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Minor | 0 | [
[
[
1394,
23,
1461
]
],
[
[
1394,
64,
581
],
[
581,
23,
1461
]
],
[
[
1394,
25,
1510
],
[
1510,
62,
1461
]
],
[
[
1394,
24,
66
],
[
66,
... | [
[
[
"Rituximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
... | Rituximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Rituximab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a minor intera... |
DB00526 | DB00710 | 1,555 | 1,199 | [
"DDInter1355",
"DDInter897"
] | Oxaliplatin | Ibandronate | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Moderate | 1 | [
[
[
1555,
24,
1199
]
],
[
[
1555,
63,
963
],
[
963,
1,
1199
]
],
[
[
1555,
24,
603
],
[
603,
63,
1199
]
],
[
[
1555,
63,
91
],
[
91,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibandronate"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zoledronic acid"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Zoledronic acid and Zoledronic acid (Compound) resembles Ibandronate (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a mode... |
DB01144 | DB09104 | 1,326 | 286 | [
"DDInter540",
"DDInter1118"
] | Diclofenamide | Magnesium hydroxide | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1326,
24,
286
]
],
[
[
1326,
63,
355
],
[
355,
23,
286
]
],
[
[
1326,
63,
688
],
[
688,
24,
286
]
],
[
[
1326,
62,
1669
],
[
1669,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol... |
DB00844 | DB11186 | 314 | 1,609 | [
"DDInter1257",
"DDInter1427"
] | Nalbuphine | Pentoxyverine | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
314,
24,
1609
]
],
[
[
314,
24,
104
],
[
104,
24,
1609
]
],
[
[
314,
63,
999
],
[
999,
24,
1609
]
],
[
[
314,
40,
421
],
[
421,
... | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazi... |
DB01193 | DB11093 | 819 | 636 | [
"DDInter12",
"DDInter273"
] | Acebutolol | Calcium citrate | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
819,
24,
636
]
],
[
[
819,
40,
88
],
[
88,
24,
636
]
],
[
[
819,
62,
542
],
[
542,
24,
636
]
],
[
[
819,
23,
115
],
[
115,
25,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a mo... | Acebutolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Acebutolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a moderate interaction t... |
DB00073 | DB14444 | 1,394 | 151 | [
"DDInter1608",
"DDInter924"
] | Rituximab | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1394,
24,
151
]
],
[
[
1394,
24,
66
],
[
66,
24,
151
]
],
[
[
1394,
25,
375
],
[
375,
24,
151
]
],
[
[
1394,
64,
1057
],
[
1057,
... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exa... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Rituximab may lead to a major life thr... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.